PitchSend

Investor Presentaiton

For personal use only Strategic priorities Use IlluccixⓇ as a commercial launchpad Create a high-value diagnostic portfolio Tx Deliver on commercial value of therapeutics Expand the pipeline Establish Telix's leadership in urologic oncology Kidney cancer imaging agent addresses major unmet need, builds on Illuccix engagement Advance late-stage assets in the core pipeline that benefit from diagnostic market entrance Novel targets, clinical applications and manufacturing technologies Telix Pharmaceuticals Limited (ASX: TLX) TELIX PHARMACEUTICALS CO 6

View entire presentation